title: Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.
abstract: The aim of this study was the discovery of nonpeptide renin inhibitors with much improved oral absorption, bioavailability, and efficacy, for use as antihypertensive agents. Our prior efforts led to the identification of A-74273 [1,R = 3-(4-morpholino)propyl], with a bioavailability of 26 +/- 10% [10 mg/kg intraduodenally (id), dog]. In vivo metabolism studies of A-74273 showed that the morpholino moiety underwent metabolic degradation. Computer modeling of A-74273 bound to renin indicated that the C-terminus was involved in a hydrogen-bonding network. New C-terminal groups were examined in two series of nonpeptides for effects on renin binding potency, lipophilicity (log P), and aqueous solubility. Those groups which possessed multiple hydrogen-bonding ability (3,5-diaminotriazole, cyanoguanidines, morpholino) provided particularly potent renin binding. Intraduodenal bioavailabilities of selected compounds, evaluated in rats, ferrets, and dogs, were higher for inhibitors with moderate solubility as well as moderate lipophilicity, in general. Although the absolute values varied substantially among species, the relative ordering of the inhibitors in terms of absorption and bioavailability was reasonably consistent. Such well absorbed inhibitors (e.g. 41, 44, and 51) were demonstrated as highly efficacious hypotensive agents in the salt-depleted dog. We report here the discovery of a series of efficacious nonpeptide renin inhibitors based on the 3-azaglutaramide P2-P4 replacement, the best of which showed id bioavailabilities > 50% in dog.
authors.affiliation: Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064.
authors.forename: S A
authors.initials: SA
authors.lastname: Boyd
authors.forename: A K
authors.initials: AK
authors.lastname: Fung
authors.forename: W R
authors.initials: WR
authors.lastname: Baker
authors.forename: R A
authors.initials: RA
authors.lastname: Mantei
authors.forename: H H
authors.initials: HH
authors.lastname: Stein
authors.forename: J
authors.initials: J
authors.lastname: Cohen
authors.forename: J L
authors.initials: JL
authors.lastname: Barlow
authors.forename: V
authors.initials: V
authors.lastname: Klinghofer
authors.forename: J L
authors.initials: JL
authors.lastname: Wessale
authors.forename: K M
authors.initials: KM
authors.lastname: Verburg
mesh_terms: D000577:Amides / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000818:Animals; D002250:Carbon Radioisotopes; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003198:Computer Simulation; D004285:Dogs; D004386:Duodenum / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption; D008954:Models, Biological; D008958:Models, Molecular; D009025:Morpholines / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats; D012083:Renin / Q000378:metabolism; D013329:Structure-Activity Relationship; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D002250:Carbon Radioisotopes; D009025:Morpholines; D012083:Renin; D000092502:Renin Inhibitors; C078248:A 74273